WROCŁAW,
CT-01 is Captor’s lead asset and is being developed as a treatment for hepatocellular carcinoma (a form of liver cancer). Earlier pre-clinical studies allowed Captor to select the best drug candidate to progress to the clinic. Captor has consequently initiated the necessary steps with this drug candidate to generate the data required to submit a Clinical Trial Authorization (CTA) and Investigational New Drug (IND) Application. These activities include larger scale manufacturing, toxicological testing and additional in-vivo efficacy testing, the latter confirming in animal models that the drug candidate causes strong tumor regression. Captor remains on track to initiate a clinical trial in 2023.
Captor continued to strengthen its partnership activities and announced an agreement with Ono Pharmaceutical Co. ltd. (which took place after the end of the reported period) to develop small-molecule compounds capable of degrading a selected molecular target, primarily for application in neurodegenerative diseases for which there is currently no effective therapy. The market for neurodegenerative diseases (i.e., a group of conditions that include, among others, Alzheimer’s disease and Parkinson's disease) is estimated to be worth tens of billions of dollars in annual sales and is growing steadily due to the aging of the population in most developed countries.
In addition to providing Captor with an upfront payment, R&D funding and potential milestones that could reach up to €197 million, in addition to royalties on sales, this agreement with Ono Pharmaceutical is a strong endorsement of Captor’s research and development capabilities. It is also a major event for the TPD field in that it is an early example of a CNS focused collaboration and indicates the wider field of therapeutic applications where TPD could be used. This discovery stage partnership is one of the larger ever signed in the Polish biotechnology market.
“The last few months have brought us closer to a significant breakthrough in the research and development of our own projects. We have also started to monetize interest in our platforms and technology from big-pharma players, as evidenced by the agreement signed with Ono Pharmaceutical. Captor is financially and technologically ready to enter its next chapter of growth. Not only do we have the capabilities to move CT-01 into the clinic and to progress our internal pipeline through pre-clinical development, but our latest advances in preclinical capabilities provide us with the necessary bandwidth to enter new strategic partnerships," said Dr. Michał Walczak, Board Member and Chief Scientific Officer of
In the third quarter of 2022, Captor generated PLN 9,175 thousand in revenue, including PLN 5,171 thousand from non-dilutive grant funding and PLN 1,110 thousand from the technology collaboration with Sosei Heptares, which aims to discover new degraders against a G protein-coupled receptor (GPCR) target.
“The development path of
About
For more information on
LinkedIn: @CaptorTherapeutics
Twitter: @CaptorTherapeu1
For more information, please contact:
Polish Media and Investor relations: Point of View +48 694 400 787 captortherapeutics@pov.pl | International Investor Relations: +41 (0)76 735 01 31 gvanrenterghem@lifesciadvisors.com |
Source:
2022 GlobeNewswire, Inc., source